Results from the pivotal DERM-SUCCESS clinical utility study show that primary care physicians using the FDA-cleared DermaSensor device correctly referred 91.4 percent of malignant skin lesions, compared to just 82.0 percent without it, a 52 percent reduction in missed cancer referrals that researchers say could meaningfully change how skin cancer is caught outside dermatology clinics.
Why Primary Care Is Where Skin Cancer Often Slips Through
Most patients first bring a suspicious mole or lesion to a primary care doctor rather than a dermatologist, but general practitioners receive comparatively little specialized training in visually distinguishing benign lesions from melanoma, basal cell carcinoma or squamous cell carcinoma. That gap matters because skin cancer, including melanoma, has a dramatically better prognosis the earlier it is caught, and delayed referral to a dermatologist for biopsy or removal can allow malignant lesions to progress before treatment begins.
How DermaSensor’s Technology Works
The device combines elastic scattering spectroscopy, a light-based technique that captures how a lesion’s tissue scatters different wavelengths of light, with an AI model trained to interpret those spectral patterns and flag lesions suggestive of cancer. In practice, a primary care physician holds the point-of-care device against a suspicious lesion, and within seconds it returns a risk assessment, a workflow the company designed specifically to fit inside the time constraints of a routine primary care visit rather than requiring a separate dermatology referral just to get an initial risk read.
The Data Behind the Approval
The FDA-cleared device has demonstrated 96 percent sensitivity in identifying the three most common skin cancers, and the joint FDA studies behind its clearance found it reduced missed skin cancer referrals in primary care by roughly 50 percent. Beyond raw accuracy numbers, the DERM-SUCCESS study also tracked physician confidence, finding that the share of primary care doctors reporting high confidence in their lesion management decisions rose from 36.8 percent to 53.4 percent when using the device, suggesting the tool changes not just outcomes but clinician decision-making behavior.
Dermatologists Offer a More Measured View
Some dermatologists have welcomed DermaSensor as a useful triage aid that could reduce unnecessary referrals for clearly benign lesions while catching more true cancers, easing pressure on a specialty that already faces long wait times for patient appointments in many parts of the country. Others caution that a point-of-care screening device is not a substitute for dermatologist-performed skin exams and biopsy, and that primary care physicians will still need clear referral pathways and follow-up protocols for any lesion the device flags as suspicious, regardless of how the sensitivity numbers look in a controlled study.
Access and Equity Considerations
Because DermaSensor is designed to work in primary care rather than requiring a dermatology visit, proponents argue it could meaningfully improve skin cancer detection in rural and underserved communities where dermatologists are scarce or booking appointments takes months. Critics note that device cost and reimbursement uncertainty could limit adoption precisely in the safety-net and rural clinics where the tool’s potential benefit is greatest, unless payers move quickly to cover its use.
What Wider Rollout Looks Like
Findings from the DERM-SUCCESS study and a companion study were published in the Journal of Primary Care and Community Health, giving primary care societies peer-reviewed evidence to point to as they consider incorporating point-of-care skin cancer screening into routine visit protocols. The company and independent researchers are expected to continue tracking long-term outcomes data, including whether increased referral accuracy translates into earlier-stage cancer diagnoses and, ultimately, improved survival rates at a population level.
Photo: kumarsu6745_ / PIXABAY via Pixabay
